? 張華北，博士, 北京師范大學教授，博士生導師。 現(xiàn)任放射性藥物教育部重點實驗室副主任，中國核學會核化學與放射化學學分會副主任委員， 中國化學會核化學與放射化學專業(yè)委員會副主任，北京核學會核醫(yī)學和分子影像專委會副主任委員，中國核學會同位素分會常務理事，中國同位素與輻射行業(yè)協(xié)會專家咨詢委員會委員，核化學與放射化學雜志副主編，同位素雜志副主編。

張華北教授是放射性藥物教育部重點實驗室主要學術(shù)帶頭人之一，長期從事藥物設計、合成、標記和生物性質(zhì)評價。正式發(fā)表論文90多篇(除少數(shù)幾篇之外均為第一作者或通訊作者), 其中許多文章發(fā)表在J. Med. Chem.，Curr. Med. Chem.，Curr. ?Pharm. ?Des.等國外重要雜志上，授權(quán)國家科技發(fā)明專利多項。主持國家16個重大科技專項重大新藥創(chuàng)制項目、國家科技支撐課題以及國家自然科學基金多項，曾獲洪堡基金在德國波斯特爾醫(yī)學和藥物研究所做高級訪問學者。

張華北教授在中國科學院組織的放射化學咨詢報告中擔任放射性藥物部分的負責人和主要撰稿人，該報告得到溫家寶總理和劉延東副總理的重要批示，主要負責起草的關于加強放射性藥物研發(fā)的建議得到了我國34位兩院院士的簽名支持。張華北教授還是國家自然科學基金委組織的無機化學學科前沿與展望一書放射化學部分的負責人和主要撰稿人。在第八屆中日雙邊放射性藥物會議和第十二屆全國放射性藥物與標記化合物會議擔任大會組委會執(zhí)行主席。

1) 計算機輔助藥物分子設計

2）藥物合成

3）放射性標記

4）生物評價

?

1、主持國家16個重大科技專項重大新藥創(chuàng)制專項（項目名稱：用于重大疾病診治的創(chuàng)新放射性藥物研制；項目 編號：2014ZX09507007，經(jīng)費：1401.06萬元：起止時間：2014.1-2017.12)

2、主持國家自然科學基金項目（項目名稱：新型神經(jīng)型煙堿乙酰膽堿α7受體顯像劑的設計與合成；項目編號： 21371026；?經(jīng)費：85元萬；?起止時間：2014.1-2017.12)

3、國家科技支撐課題（課題名稱：腦受體等五種放射性藥物研究；課題編號：2014BAA03B03，經(jīng)費：363萬元）

4、主持橫向課題（項目名稱：錒系與鑭系元素配位化學計算, 經(jīng)費：10萬元；起止時間:2011.1-2014.12）

5、主持橫向課題（項目名稱：放射性藥物影像學研究（二期），?經(jīng)費：5萬元；起止時間:2014.3-2014.6）

1. Zeng HH， Zhang HB*，Synthesis and biological evaluation of fatty acids conjugates bearing cyclopentadienyl-donors incorporated [(99m)Tc/Re(CO)3](+) for myocardical imaging， Eur. J. Med.?Chem.2014，24(72):10-7

2. YuHJ,?Fang Y,?Lu X, ?Liu?YJ, ?Zhang HB*，Combined 3D-QSAR, Molecular Docking, Molecular Dynamics Simulation, and Binding Free Energy Calculation Studies on the 5-Hydroxy-2H-Pyridazin-3-One Derivatives as HCV NS5B Polymerase Inhibitors, CHEMICAL BIOLOGY & DRUG DESIGN?，2014, 83:?89-105

3. Zeng HH, Zhao LZ, Hu SY, Liu YJ, Yu HJ, Chen N, Zhang HB*.,Synthesis, characterization and biodistribution of new fatty acids conjugates bearing N,N,N-donors incorporated [(99m)Tc/Re(CO)(3)](+), ?Dalton Trans.2013,?42(8):2894-901.

4. Lu X, Zhao LZ, Xue T, Zhang HB*, Technetium-99m- Arg-Arg-Leu(g2), a modified peptide probe targeted to neovascularization in molecular tumor imaging, J BUON.2013 ;18(4):1074-81.

5. Hu S, Yu H, Liu Y, Xue T, Zhang H.?Insight into the binding model of new antagonists of kappa receptor using docking and molecular dynamics simulation.?J Mol Model.2013，19(8):3087-94.

6. Zeng HH, Zhang HB, Wu XX, Preliminary studies of a novel cyclopentadienyl tricarbonyl technetium-99m fatty acid derivative for myocardical imaging, JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS?，2013，56(1): 1-5.?

7. Liu YJ,?Yu HJ,?Zhao, LZ, Zhang HB*, Design and synthesis of new agents for neuronal nicotinic acetylcholine receptor (nAChRs) imaging,?NUCLEAR MEDICINE AND BIOLOGY,2013,?40(1): 126-134 ?

8. Liu YJ, Yu HJ, Zhao, LZ, Zhang HB*,Design and synthesis of new agents for neuronal nicotinic acetylcholine receptor (nAChRs) imaging, NUCLEAR MEDICINE AND BIOLOGY 40(1): 126-134,2013.

9. Zhao, Lingzhou; Liu, Yongjuan; Hu, Shiyuan; ZhangHB* , 3D-QSAR study of Chk1 kinase inhibitors based on docking, JOURNAL OF MOLECULAR MODELING,?2012,18(8): 3669-3694

10. Chen Na; Liu Chunkai; Zhao Lingzhou, Zhang Huabei*, 3D-QSAR study of multi-target-directed AchE inhibitors based on autodocking, MEDICINAL CHEMISTRY RESEARCH, 21(2): 245-256,2012

11．Zeng H, Zhang H, Jang F, Zhao L, Zhang J. Molecular Modeling Studies on Benzimidazole Carboxamide Derivatives as PARP-1 Inhibitors Using 3D-QSAR and Docking, Chem Biol Drug Des.?2011,78(3):333-52.

12．Zeng Huahui; Zhang Huabei，Domestic Advances in Brain, Heart, and Tumor Radioactive Diagnosis Drugs，PROGRESS IN CHEMISTRY，2011，23（7）: 1485-1492

13．Yang Yang; Zhu Lin; Chen Xiangji，Binding research on flavones as ligands of beta-amyloid aggregates by fluorescence and their 3D-QSAR, docking studies， JOURNAL OF MOLECULAR GRAPHICS & MODELLING2010，29( 4): 538-545

14．Yang Y, Zhu L, Cui MC, Tang RK, Zhang HB* ?Preparation of classical Re/Tc-99m(CO)(3)(+) and novel Tc-99m(CO)(2)(NO)(2+) cores complexed with flavonol derivatives and their binding characteristics for A beta((1-40)) aggregates，BIOORGANIC & MEDICINAL CHEMISTRY LETTERS，2010， 20（ 17）: 5337-5344

15．Zeng HH, Zhang HB*，Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors， JOURNAL OF MOLECULAR GRAPHICS & MODELLING，2010, 29（1）， 54-71， 2010

16．Cao R, Mi N, Zhang H*. 3D-QSAR study of c-Src kinase inhibitors based on docking.

J Mol Model. 2010，16(2):361-75.

17．Yang Y, Zhang JX, Zhu L, Zhang H* Synthesis, Novel Crystal Structure, and beta-Amyloid Binding Property of Re(I) (tricarbonyl) EHIDA Analogue Bioinorg Chem Appl. 2009:702730.

18．Cao R, Mi N, Zhang H*.,3D-QSAR study of c-Src kinase inhibitors based on docking.J Mol Model. 2010 Feb;16(2):361-75.

19．Yang Y, Zhu L, Zhang HB*. Di-tert-butyl 2,2’-[(2-hydroxyethyl)azanediyl] diacetate ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE ?2009，65（12）3167-U1248.

20．Cao R, Zeng H, Zhang H*.，3D-QSAR studies on a series of inhibitors docked into a new homology model of the DNA-PK receptor.?Curr. ?Pharm. ?Des. 2009; 15(32): 3796-825.

21．Cao HY, Cao R, Zhang HB*, Zheng XF, Gao DB，Non-nucleoside Inhibitors of NS5B Polymerase Binding to Allosteric Sites: 3D- QSAR and Molecular Docking Studies，Curr. Med. Chem., 2008，15: 1462-77.

22．Zhang HB*, Hu SP, Zhang YL. Prediction of distribution of neutral, acidic and basic structurally diverse compounds between blood and brain by the nonlinear methodology. Med Chem. 2008 , 4:170-89.

23． Zhang HB*, Li H, Ma QQ QSAR study of a large set of 3-pyridyl ethers analogues，Journal of Molecular Graphics and Modelling, 2007, ?26: 226-235.

24． Cao HY, Zhang HB*，Zheng XF, Gao DB，3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family，Journal of Molecular Graphics and Modelling, 2007, 26:236-245.

25. Zhang HB*, Zhang YL, ?Convenient Nonlinear Model for Predicting the Tissue/Blood Partition Coefficients of Seven Human Tissues of Neutral, Acidic and Basic Structural-Diverse Compounds, J. Med. Chem., 2006，49:, 5815-5829.

26. Zhou JM, Zhou JH, Zhang HB, et al. Fluoro-substitution effects in deoxyfluoro-D-glucose derivatives: random conformational search and quantum chemical calculation?, CARBOHYDRATE RESEARCH, 2006, 341: 2224-2232.

27. Zhang HB*, A QSAR Study of the Brain/Blood Partition Coefficients on the Basis of ?pKa Values, QSAR & combinary chemistry, 2006, 25:, 15-24.

28. Zhang HB*, Li H, Liu CP，CoMFA, CoMSIA and Molecular Hologram QSAR Studies of Novel Neuronal nAChRs Ligands u2013 Open Ring Analogues of 3-pyridyl Ether，J. Chem. Inf. model. 2005, 45: 440-448.

29. Zhang HB*, Ye HH, ?Zhang YL , et al.Synthesis, biodistribution and QSAR studies of five Tc-99m labeled novel N3S pseudo-peptide complexes， Med. Chem. Res. 2005, 14: 40-56.

30. Zhang HB*, A new approach for the tissue-blood partition coefficients of neutral and ionized compounds, J. Chem. Inf. model. 2005, 45:121-127.

?

張華北，u2002趙凌舟；u2002盧霞；u2002薛甜， 一種具有粘著斑激酶抑制作用的嘧啶類化合物及其制備方法和應用，專利號：2012105919329，授權(quán)公告日：2015-4-29

?

張華北；曾華輝；u2002于海靜，新型锝-99m標記的高級脂肪酸衍生物，專利號：2011101492546，授權(quán)公告日：2014-06-25

?